the FDA approved Enhertu in stomach cancer following prior treatment with a trastuzumab (Herceptin)-based regimen. That second-line nod was based on results from the phase 2 Destiny-Gastric01 ...

The DESTINY-Gastric04 study is comparing Enhertu (trastuzumab deruxtecan ... who have progressed on or after a trastuzumab-containing regimen. The interim results "demonstrated a statistically ...

a standard regimen for this type of cancer. In the DESTINY-Breast03 trial, Enhertu reduced the risk of disease progression or death by 72% versus Roche's Kadcyla (trastuzumab emtansine), which has ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

A strong trend favoring the Imfinzi-based regimen was also observed for the ... recommending the approval of Enhertu for certain breast cancer patients in the European Union.

Q4 2024 Earnings Call Transcript March 7, 2025 Oncolytics Biotech Inc. beats earnings expectations. Reported EPS is $-0.06949, expectations were $-0.08. Operator: Good morning, and welcome to ...

The sponsor should acknowledge that the indication authorized under the NOC/c pathway for Enhertu under control number 285834 can be withdrawn or revised, pending the outcome of Study U306. The ...

In this regimen, patients are treated with Imfinzi in combination ... and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan) in ...

Positive results from the phase 3 DESTINY-Gastric04 trial (NCT04704934) have confirmed the efficacy of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with ... after a ...